Prediabetes Market to Grow with a CAGR of 11.02% through 2030

Growing adoption of digital health tools for blood glucose monitoring, and expanding healthcare initiatives focused on metabolic disorder prevention, is expected to drive the Global Prediabetes Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Prediabetes Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Prediabetes Market stood at USD 324.51 Million in 2024 and is expected to reach USD 608.46 Million by 2030 with a CAGR of 11.02% during the forecast period. The Global Prediabetes Market is evolving as a critical segment of chronic disease prevention, driven by the growing recognition of metabolic syndrome and insulin resistance as public health priorities. Increased screening in general population health checkups and the inclusion of glycemic risk indicators in routine diagnostics have elevated the clinical relevance of prediabetes management. Health systems are gradually shifting focus from reactive diabetes care to preventive strategies aimed at reducing the economic and social burden of long-term complications. Pharmaceutical companies and healthcare providers are exploring the prediabetes space not only for drug development but also for non-pharmacological interventions, such as coaching programs and behavior modification therapies. As a result, a broader range of stakeholders is entering the market, from tech start-ups to wellness companies.

One of the emerging trends in the market is the convergence of nutrition science and metabolic health. Functional foods, dietary supplements, and nutraceuticals designed to support insulin sensitivity and glucose metabolism are gaining attention among consumers and clinicians. Public interest in low-glycemic diets, plant-based nutrition, and intermittent fasting is aligning with clinical recommendations, creating new commercial pathways. The rise of workplace wellness programs and corporate-sponsored preventive health checkups is encouraging early diagnosis and lifestyle changes. Healthcare providers are also adopting remote coaching and teleconsultation services for prediabetic patients, ensuring consistent engagement. These consumer-focused solutions reflect a broader shift in healthcare, where empowerment and convenience are becoming central to long-term disease prevention strategies.

Growth opportunities in the Global Prediabetes Market lie in the untapped potential of personalized prevention models. Advancements in genomics, microbiome analysis, and metabolic profiling are paving the way for precision healthcare solutions tailored to an individual's risk factors and lifestyle. Companies investing in digital therapeutics and AI-powered platforms for behavioral intervention and predictive analytics are well-positioned to capitalize on this shift. There is also significant room for market expansion in underserved regions, where educational outreach and mobile health clinics can bridge access gaps. Collaborations between governments, insurers, and private companies to incentivize preventive care through subsidies and wellness incentives could accelerate adoption. As prediabetes becomes a focal point in global health policy, innovators who combine affordability, accessibility, and customization will lead the next phase of market growth.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Prediabetes Market”

The Global Prediabetes Market is segmented into drug class, age group, regional distribution, and company.

Based on the Drug Class, Glucagon-like peptide-1 agonists (GLP-1) emerged as the fastest growing segment in the Global Prediabetes Market during the forecast period. This is due to their multifaceted benefits in glucose regulation and weight management. GLP-1 receptor agonists mimic the natural incretin hormone, enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying, which collectively contribute to better glycemic control and reduced appetite. These mechanisms make GLP-1 agonists particularly effective for individuals with prediabetes who are overweight or obese two major risk factors for progressing to type 2 diabetes. The increasing clinical evidence supporting their role in delaying diabetes onset and improving cardiometabolic outcomes is driving higher adoption rates globally. The growing acceptance of GLP-1 therapies for prediabetic populations is also supported by innovations in drug delivery, including once-weekly injectables and emerging oral formulations, which improve convenience and patient adherence.

Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global Prediabetes Market during the forecast period. This is due to the growing emphasis on preventive care and chronic disease management. This shift is supported by expanding health insurance coverage in urban and semi-urban areas, allowing more individuals to access diagnostic and therapeutic interventions at earlier stages of the disease. In addition, the region has become a focal point for clinical research and pharmaceutical investments targeting diabetes and metabolic conditions. The emergence of local players offering cost-effective prediabetes treatments, coupled with increasing collaborations between regional healthcare systems and international organizations, is further accelerating market growth. Countries such as Japan and South Korea are leading in digital health innovation, contributing to the adoption of mobile health apps, telemedicine services, and wearable devices for glucose monitoring and lifestyle tracking. These tools enhance patient engagement and promote real-time monitoring, leading to better outcomes and increased awareness of prediabetes.

Major companies operating in Global Prediabetes Market are:

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca
• Bristol-Myers Squibb Company
• Pfizer Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Global Prediabetes Market is expanding due to the rising adoption of employer-sponsored wellness programs and corporate healthcare initiatives that aim to mitigate long-term health risks by addressing prediabetes at an early stage. With increasing healthcare costs and productivity losses linked to chronic diseases, employers across various sectors are investing in regular health screenings, metabolic risk assessments, and lifestyle coaching for their workforce. These programs not only improve early diagnosis but also encourage behavioral changes through education and incentivized participation. As more organizations integrate digital health tools and partner with health service providers to monitor employee health, the demand for prediabetes-related diagnostics and interventions is witnessing steady growth.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Prediabetes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Biguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others), By Age Group (Children (12-18 years), Adults (18-49), Elderly (50+)), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Prediabetes Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Prediabetes Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com